Henriette Ingrid Melzer

Learn More
To analyse the diagnostic value of 18F-FDG PET and MRI for the evaluation of active lesions in paediatric Langerhans cell histiocytosis. We compared 21 18F-FDG PET scans with 21 MRI scans (mean time interval 17 days) in 15 patients (11 male, 4 female, age range 4 months to 19 years) with biopsy-proven histiocytosis. Primary criteria for the lesion-based(More)
To analyse different uptake patterns in 123I-MIBG scintigraphy/SPECT imaging and 18F-FDG PET in paediatric neuroblastoma patients. We compared 23 123I-MIBG scintigraphy scans and 23 18F-FDG PET scans (mean interval 10 days) in 19 patients with a suspected neuroblastic tumour (16 neuroblastoma, 1 ganglioneuroblastoma, 1 ganglioneuroma and 1 opsomyoclonus(More)
The present study compares the diagnostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) and MRI to combined/registered 18F-FDG PET/MRI for staging and restaging in paediatric oncology. Over 8 years and 2 months, 270 18F-FDG PET and 270 MRI examinations (mean interval 5 days) were performed in 132 patients with proven (n = 117) or(More)
The aim of this study was to evaluate the diagnostic value of contrast-enhanced CT (CECT) versus non-enhanced low-dose CT (NECT) in the staging of advanced malignant melanoma with 18F-fluordeoxyglucose (FDG) positron emission tomography (PET)/CT. In total, 50 18F-FDG PET/CT examinations were performed in 50 patients with metastasized melanoma. For(More)
Scintigraphy using 123I-metaiodobenzylguanidine (123I-MIBG) is widely used for the detection of neuroblastic tumours. The aim of this study was to identify a possible correlation between the uptake intensity on 123I-MIBG SPECT and histopathology of neuroblastic tumours. 123I-MIBG SPECT examinations were performed in 55 paediatric patients with neuroblastic(More)
  • 1